Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
But now these molecules are heavily available and there are many substitutes in market which created the effect on business, now this segment is mainly control by how much a company can able to sell means this segment is heavily volume growth and not value, if we see segment revenues for the companies, we can see that sales might be rising with years but margin are not expanding that's why companies with only older oral drugs struggle to create shareholder value
Technically yes, but it's not recommended
Jensen L, Helleberg H, Roffel A, Jaap van Lier J, Bjornsdottir I, Pedersen PJ, et al
Thats because demand for GLP-1s has skyrocketed over the last year, with users more than doubling from 2024
Medical Disclaimer: This article is for informational purposes only and is not medical advice
